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Abstract
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Greater integration of medication-assisted treatment (MAT) for opioid use disorder (OUD) in U.S.
primary care settings would expand access to treatment for this condition. Models for integrating
MAT in primary care vary in how they are structured. This paper summarizes findings of a
technical report for the Agency for Healthcare Research and Quality (AHRQ) describing OUD
MAT models of care, based on a literature review and interviews with key informants in the field.
The report describes 12 representative models of care for integrating MAT in primary care settings
that could be considered for adaptation across diverse healthcare settings. Common components of

Correspondence: P. Todd Korthuis, MD, MPH, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Mail Code
L-475, Portland, OR 97239-3098, Phone: 503-494-8044, Fax: 503-494-0979, korthuis@ohsu.edu.
P. Todd Korthuis and Melissa Weimer: Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code L-475,
Portland, OR 97239-3098
Dennis McCarty: OHSU-PSU School of Public Health, CB669, 3186 SW Sam Jackson Park Road, Portland, OR 97239
Beth Devine: University of Washington, Box 357630, Seattle, WA 98195-7630
Roger Chou, Christina Bougatsos, Ian Blazina, Bernadette Zakher, Sara Grusing: Oregon Health & Science University, 3181 SW Sam
Jackson Park Road, Mail Code: BICC, Portland, OR 97239

Author Manuscript

Disclaimer: The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as
endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. AHRQ
retains a license to display, reproduce, and distribute the data and the report from which this manuscript was derived under the terms of
the agency’s contract with the author.
Role of the Funder: This topic was selected by AHRQ for systematic review by an EPC. A representative from AHRQ served as a
Contracting Officer’s Technical Representative and provide technical assistance during the conduct of the full evidence report and
provided comments on draft versions of the full evidence report. AHRQ did not directly participate in the literature search,
determination of study eligibility criteria, data analysis or interpretation, or preparation, review, or approval of the manuscript for
publication.
This is the prepublication, author-produced version of a manuscript accepted for publication in Annals of Internal Medicine. This
version does not include post-acceptance editing and formatting. The American College of Physicians, the publisher of Annals of
Internal Medicine, is not responsible for the content or presentation of the author-produced accepted version of the manuscript or any
version that a third party derives from it. Readers who wish to access the definitive published version of this manuscript and any
ancillary material related to this manuscript (e.g., correspondence, corrections, editorials, linked articles) should go to Annals.org or to
the print issue in which the article appears. Those who cite this manuscript should cite the published version, as it is the official
version of record.

Korthuis et al.

Page 2

Author Manuscript

existing care models include (1) pharmacotherapy with buprenorphine or naltrexone, (2) provider
and community education, (3) coordination/integration of OUD with other medical/psychological
needs, and (4) psychosocial services/interventions. Models varied with respect to how each
component is implemented. Decisions about adopting MAT models of care should be
individualized to address the unique milieu of each implementation setting.

INTRODUCTION
The U.S. Department of Health & Human Services identifies opioid use disorder (OUD) as a
national crisis (1). In 2014, approximately 1.9 million Americans 12 years or older were
estimated to have OUDs linked to use of prescription opioids and nearly 600,000 used
heroin (2). In 2013, an estimated 16,000 people died as a result of prescription opioid
overdose and approximately 8,000 from heroin (3).

Author Manuscript
Author Manuscript

Medication-assisted treatment (MAT) for OUD, also referred to as “pharmacotherapy,”
decreases illicit opioid use, prevents relapse, improves health, and reduces the risk of death
from OUD (4). Medications currently approved by the U.S. Food and Drug Administration
include a full agonist (methadone), partial opioid agonists (buprenorphine, buprenorphine/
naloxone, and implantable buprenorphine), and opioid antagonists (oral and extendedrelease naltrexone). These medications block the euphoric and sedating effects of opioids,
reduce craving for opioids, and/or mitigate opioid withdrawal symptoms. MAT is more
effective than non-medication treatment alone in reducing opioid use (5, 6). Behavioral
therapy addresses the psychosocial contributors to OUD and may augment retention in
treatment. The Office of National Drug Control Policy (ONDCP) and the Department of
Health & Human Services recently prioritized increasing access to MAT to address the OUD
epidemic (1, 7).
Integrating MAT in primary care settings expands access to OUD treatment (8). The Drug
Abuse Treatment Act (DATA) of 2000 enabled physicians to prescribe buprenorphine for
treatment of OUD but use remains limited (3, 9, 10). Understanding the most effective and
promising models of care is critical for optimizing initiatives to expand access to MAT (1).
Because not all MAT models are published and outcomes of different MAT models have not
been compared, the Agency for Healthcare Research and Quality (AHRQ) commissioned a
scoping review to develop a taxonomy of OUD MAT models of care, focused on primary
care settings.

METHODS
Author Manuscript

Scope of the Review
Our standardized review protocol and methods are detailed in the full report (11)
(www.effectivehealthcare.ahrq.gov/reports/final.cfm). The review described representative
MAT models of care in primary care settings and did not provide an exhaustive list of
models for MAT integration. Representative models were selected based on their influence
on current clinical practice, innovation, or their focus on MAT for specific primary care
populations or settings.
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Eleven key informants (8 nonfederal and 3 federal) with experience implementing OUD
MAT in primary care setting were interviewed between March and June 2016 (Table 1). We
facilitated small group telephone discussions using a semi-structured guide (Appendix A)
asking participants to identify MAT models used in primary care, including unpublished
models, and asked them to specify key model components. Calls were recorded, summarized
and shared with the group for clarification and additional input. Based on Key Informant
input, we developed a framework categorizing MAT model key components to provide a
structure for future research and discussions. We then integrated input from the Key
Informants with published and unpublished literature.

Author Manuscript

We searched for literature describing MAT models in primary care settings or their
effectiveness from 1995 through June 2016 using Ovid Medline, PsycINFO, the Cochrane
Library, SocINDEX, and CINAHL databases (Appendix B). We also reviewed reference
lists and solicited additional references from Key Informants. We searched the grey literature
(ClinicalTrials.gov, Health Services Research Projects in Progress (HSRProj), Google
Scholar, NIH Reporter, and Web sites of government agencies with MAT initiatives), and
sent an email notification to stakeholders about the opportunity to submit Scientific
Information Packets for ongoing or unpublished research. The literature review provided
descriptive/contextual information on the models to supplement Key Informant interviews.
The search identified 5,892 abstracts; we reviewed 475 full text articles, 27 of which
informed descriptions of MAT models of care, along with 13 grey literature citations (Table
2).

RESULTS
Author Manuscript

Key Informants consistently noted four key components of MAT models in primary care: (1)
pharmacotherapy with buprenorphine or naltrexone; (2) provider and community
educational interventions (e.g. in-person, web-based, and telehealth provider CME activities,
community-based advertising campaigns, stakeholder conferences); (3) coordination/
integration of OUD treatment with other medical/psychological needs; and (4) psychosocial
services (e.g. counseling on-site or by referral). Models varied in the degree of component
implementation.

Author Manuscript

Table 3 summarizes 12 representative models of MAT care and how the 4 key components
are addressed. We included models that contained the 4 key components and met criteria for
effectiveness, innovation, and/or addressing special populations (e.g. rural settings, HIV,
prenatal care). Ten models were described by Key Informants, six in the published literature,
and seven in unpublished/grey literature sources (Table 2). We categorized four models as
primarily practice-based and 8 as systems-based, though most have elements of both. For
each model, we discuss the clinician, practice, and system-level factors, including financing,
evidence of effectiveness, challenges, and situations in which the model is most likely to be
feasible and effective.
Practice-Based Models
Office-Based Opioid Treatment—In Office-Based Opioid Treatment (OBOT),
physicians who complete 8 hours of training and receive a DEA waiver number may
Ann Intern Med. Author manuscript; available in PMC 2017 August 21.
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prescribe buprenorphine/naloxone in the context of primary care (12, 13). While many
providers offer OBOT without staff assistance, some practices designate a clinic staff
member (often a nurse or social worker) to coordinate buprenorphine prescribing (14–16).
Psychosocial services include on-site brief counseling provided by the physician or other
staff and/or off-site referrals. OBOT is financed through provider reimbursement of billable
visits. Medicare and many state Medicaid programs cover buprenorphine, though prior
authorization is frequently required. The SAMHSA-funded Provider’s Clinical Support
System for MAT (http://pcssmat.org/) is a free systems-level resource that supports OBOT
implementation nationally with provider education and mentoring. Retention in treatment
and opioid use outcomes with OBOT are comparable to methadone treatment programs,
with 38% retention at 2 years and 91% of urine toxicology screens negative for opioid
among those retained in one long-term cohort study (14).

Author Manuscript

OBOT may be particularly advantageous for reaching persons with OUD who are already
engaged in primary care, and offers an alternative for patients who cannot access methadone
treatment programs. Challenges include a variable scope of psychosocial services and
structure required for management of complex patients. Also, nurse practitioners and
physicians assistants—important providers of primary care in rural areas—are currently not
eligible to prescribe buprenorphine.

Author Manuscript

Buprenorphine HIV Evaluation and Support Collaborative Model—The
Buprenorphine HIV Evaluation and Support (BHIVES) Collaborative model adapted the
OBOT framework to integrate buprenorphine in HIV primary care (17–26). HIV primary
care providers in 9 HIV clinics provided buprenorphine along with HIV primary care,
facilitated by a non-physician coordinator and variable on-site psychosocial services. The
BHIVES cohort of 303 participants receiving buprenorphine demonstrated 49% treatment
retention at 12 months; past 30 days opioid use decreased from 84% at baseline to 42%
among those retained at 12 months (18). BHIVES is recommended as the standard of care
for engaging HIV-infected patients with OUD in treatment (27–29). Buprenorphine and HIV
care are typically covered by patient insurance. Ryan White Care Act (30) funding
supplements medication coverage, care coordination and counseling services in some states.
An advantage of the BHIVES model is that it addresses MAT, HIV care, and primary care
within a single setting, and patients view this model as patient-centered (31). Challenges
include limited financial support for on-site counseling in clinics without designated Ryan
White funding. Provider’s Clinical Support System for MAT includes physician mentors
with expertise in HIV care.

Author Manuscript

One Stop Shop Model—The One Stop Shop model was developed in response to an
outbreak of HIV infection in rural Indiana due to sharing of infected syringes (32) where
there were no prior OUD or HIV treatment services. Based in an existing mental health
clinic, it provides integrated care for HIV and hepatitis C infection, MAT, mental health,
primary care, and syringe exchange (33). A primary care provider embedded in the mental
health clinic prescribes extended-release naltrexone as the primary pharmacological
component as well as antiretroviral therapy. Financing is from a combination of existing
Medicaid and federal funding. While comprehensive care is attractive in any setting, this
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model might be particularly useful for rapid deployment in other specific OUD and HIV
outbreaks. However, it requires rapid training of a willing local providers, state and federal
resources for outbreak response, and its effect on outcomes and reproducibility in other
settings has not been assessed.

Author Manuscript

Integrated Prenatal Care and Medication-Assisted Treatment—This model
provides prenatal care to pregnant women who are treated with buprenorphine in primary
care. Women receive prenatal and postpartum care, with OBOT buprenorphine maintenance
continued following delivery. Psychosocial services are provided on-site in some practices,
or through affiliated OTPs. While outcomes in primary care-based settings have not been
assessed, outcome studies conducted in OTPs suggest that there is reduced Neonatal
Abstinence Syndrome when pregnant women with OUD are maintained with buprenorphine
rather than methadone (34, 35). This model is typically financed through existing Medicaid
and other insurance reimbursement. Advantages include identification of women not
previously engaged in OUD care, increased maternal motivation for OUD treatment due to
concerns about the fetus, and provision of ongoing MAT maintenance in the postpartum
period. A potential challenge is that the physician may reach their buprenorphine prescribing
limit as more women seek to continue maintenance treatment following delivery.
Systems-Based Models

Author Manuscript
Author Manuscript

Medicaid Health Home Model—The Medicaid health home model is a flexible federal
program through Centers for Medicare and Medicaid Services that allows states that apply
for a Medicaid waiver to integrate MAT and behavioral health therapies with primary care
for patients with OUD (36, 37). Primary care physicians prescribe buprenorphine as the
primary pharmacotherapy, financed through usual Medicaid insurance coverage. Provider
and community education (e.g. provider outreach, CME conferences, and community
advertising) is emphasized to increase uptake by clinicians and patients and to decrease
stigma. Robust psychosocial services are required. Demonstrations in Rhode Island and
Maryland implemented Medicaid health home models in OTPs or psychiatric clinics, rather
than in primary care clinic settings (37). States determine the structure of health care
delivery, for example with Hub and Spoke models in Vermont, and approach to payment,
which may include per member per month payments (Maryland) and weekly bundled
payments (Rhode Island) that fund care coordinators in addition to other billable health care
services. Advantages include required care coordination and core psychosocial services, an
emphasis on provider and community education, and flexibility in enabling service delivery
and provision according to the needs and resources of a particular state. Opioid health home
models may be particularly well-suited for states with a high prevalence of OUD and state
governments seeking payment structures that promote broader integration of primary care,
psychosocial, and MAT services for OUD.
Hub and Spoke Model—The Hub and Spoke model, developed in Vermont, triages
patients to two levels of care based on need during initial screening (38–41). “Spokes” are
primary care clinics that provide MAT for less complex patients using an OBOT approach.
“Hubs” are regional opioid treatment programs (OTPs) that care for more complex patients,
dispense methadone if needed, support tapering off MAT, and provide consultative services
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to the spokes. Following stabilization, patients initially managed at a hub may transfer to a
spoke; conversely, patients managed in a “spoke” who require a higher level of care may be
transferred to a hub. Buprenorphine has been the primary pharmacotherapy in this model.
Vermont incentivized implementation of buprenorphine prescribing by funding online
buprenorphine waiver training for “spoke” physicians and other technical assistance. They
also incentivized “hubs” by funding behavioral health specialists. Coordination and
integration occur between the hub and spoke and within each spoke, and is typically carried
out by a registered nurse or clinician case manager. Psychosocial services are embedded
within spokes, including social workers, counselors, and community health teams. The
model is financed through a Medicaid health home model waiver state block grant. Its effect
on outcomes has not been published. The Hub and Spoke model may be particularly suited
for states with rural OUD populations where limited treatment services are available.
Important advantages of the Hub and Spoke model include the availability of tiered care and
integration of primary care with regional OUD management expertise, use of care
coordinators and embedded psychosocial services at the spoke sites. Potential challenges
include the unavailability of OTP hubs in all settings that wish to implement MAT.

Author Manuscript
Author Manuscript

Project Extension for Community Healthcare Outcomes—Project Extension for
Community Healthcare Outcomes (ECHO) links primary care clinics in rural New Mexico
with a university health system utilizing an Internet-based audiovisual network for
mentoring and education (42–44) and has been adapted to support rural primary care
providers in MAT management. It emphasizes nurse practitioner- or physician assistantbased screening with referral to a collaborating physician prior to initiation of MAT and for
ongoing treatment. Counseling and behavioral therapies are offered from all ECHO team
members during weekly teleconferences. Complex patients can be referred to an OTP.
ECHO recruits physicians for buprenorphine waiver training and provision of continuing
medical education in OUD. The ECHO model may be considered a rural adaptation of the
Hub and Spoke or Collaborative Opioid Prescribing models, in that it engages the expertise
of a virtual “hub” center to assist in provision of MAT via teleconference. It is financed
through various federal grants and Medicaid. While patient-level outcomes have not been
assessed, an ECHO program evaluation noted increased numbers of rural primary care
providers with buprenorphine prescribing waivers per capita in New Mexico (42).
Advantages include a strong emphasis on psychosocial services, Continuing Medical
Education credits for teleconference participation, and collaboration with mid-level rural
providers for initial screening. This model is well-suited for enhancing rural primary care
provider capacity to treat patient with OUD. Challenges include limited availability of faceto-face expertise in MAT for high-risk patients, and lack of direct contact between off-site
experts and patients.
Collaborative Opioid Prescribing Model—The Collaborative Opioid Prescribing
model, developed in Maryland (45, 46), is another tiered model of care with centralized
initial intake, buprenorphine induction and stabilization at an OTP, followed by transfer to
primary care clinicians for ongoing MAT. Unlike the Hub and Spoke model, OTPs perform
intake and induction/stabilization in all patients, and provide ongoing psychosocial services
for patients transferred to primary care. Its effect on patient outcomes has not been assessed.
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This model is likely to be well-suited for primary care practices that are geographically close
to OTPs. Financing is through Medicaid and private insurance. Advantages are similar to
Hub and Spoke, with the addition of ongoing OTP psychosocial services. Challenges include
the geographic proximity required between OTP and primary care sites and limited OTP
capacity to provide ongoing support as more patients transfer to primary care.

Author Manuscript
Author Manuscript

Massachusetts Nurse Care Manager Model—Massachusetts Medicaid reimburses
nurse care managers in Federally Qualified Health Centers (FQHC) when supporting
physicians to provide buprenorphine or naltrexone using either partial agonists or
antagonists for opioid use disorders. The nurse care manager performs patient screening,
intake, and education and scheduling with a prescriber and facilitates ongoing medical and
OUD management. The prescribing physician confirms the OUD diagnosis and
appropriateness of MAT and co-manages the patient with the nurse care manager.
Psychosocial services are integrated on-site or nearby. Patients who require a higher level of
care receive expedited OTP referral. The model is financed through direct Medicaid
reimbursement to FQHCs for nurse care manager time as a billable service, in addition to
usual Medicaid coverage for pharmacotherapy and physician visits. A cohort study of 408
pilot patients enrolled in this program reported 51% had engaged in buprenorphine treatment
at one year and 91% of those retained on buprenorphine at 12 months had urine toxicology
screens negative for opioids (47). Advantages include utilization of a skilled non-physician
to offload prescribing physician burden, an emphasis on provider training, and financial
sustainability through Medicaid-reimbursed nurse care manager visits. This model may be
attractive over a wide range of primary care practices in states with Medicaid programs or
other payers that could adopt reimbursement of nurse care manager visits for OUD. An
evaluation of statewide scale-up noted a 375% increase in the number of buprenorphinewaivered physicians within 3 years (48). Challenges include variable availability of
psychosocial services and nurse care managers trained in MAT management and, in most
states, a lack of Medicaid coverage for nurse OUD care management.

Author Manuscript

Emergency Department Initiation of Office-Based Opioid Treatment—This
model focuses on emergency department (ED) identification of OUD, and initiation of
buprenorphine (49). ED physicians assess patients for OUD and begin buprenorphine
induction in appropriate candidates during their ED visit. Patients are discharged with
instructions for continuation of home induction and stabilization doses and connected to
primary care OBOT for ongoing management. Brief physician counseling is performed
during the ED visit and other psychosocial services vary. A randomized trial of ED-initiated
buprenorphine versus referral or brief intervention demonstrated 78% engagement in
buprenorphine treatment at 30 days compared with 37% in the referral group and 45% in the
brief intervention group. The number of days of illicit opioid use per week decreased from
5.4 days to 0.9 days in the buprenorphine group versus 5.4 to 2.3 days in the referral group
and 5.6 to 2.4 days in the brief intervention group (49). Medications, ED visits, and OBOT
are funded through patient Medicaid and other insurance plans. This model is promising for
scale-up to other ED settings with high prevalence of OUD and strong linkages to primary
care OBOT. Advantages include enhanced access to MAT for patients who may not be
accessing primary care or OTP, and improved engagement in OUD treatment compared with
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passive referral. Potential challenges include added congestion in the ED as a means to
access treatment.
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Inpatient Initiation of Medication-Assisted Treatment—This model identifies OUDs
among hospitalized patients, initiates MAT, and links to ongoing community-based
treatment following discharge (50–52). Financing is from Medicaid and other insurance
coverage, often requiring prior authorizations for outpatient prescriptions prior to hospital
discharge. Linkage with ongoing psychosocial services varies. In one study, 72% of
inpatients with OUD randomized to buprenorphine stabilization engaged in OBOT versus
12% of those randomized to buprenorphine detoxification (50). This model requires hospital
support for initial development of inpatient consult services. Advantages include inpatient
screening and initiation includes identification of patients with complex morbidity and high
risk of mortality who may not otherwise access MAT, increased retention in care, and
potential for linkage to OBOT for ongoing management. Patients initiated on methadone,
which cannot be prescribed by primary care providers for OUD, would not be eligible for
OBOT referral.

Author Manuscript

Southern Oregon Model—The Southern Oregon Model is an example of a local,
informal model for MAT delivery in a network of rural primary care clinics. It focuses on
OBOT with buprenorphine and utilizes regular meetings of regional stakeholders, including
regional Medicaid-accountable care organizations (53) and primary care providers, for
education, training, and development of practice standards around opioid prescribing for
chronic pain and OUD treatment. Coordination or integration of care is variable and often
limited, though an on-site clinical social worker is available in some clinics. The model is
financed through direct support from Accountable Care Organizations and usual fee for
service billing. The model may be well-suited for rural health providers in Affordable Care
Act states with Accountable Care Organizations that promote community-wide support for
opioid MAT. An advantage of this model is that it is a grass roots, community-based effort,
which may promote buy-in from clinicians and the community to overcome stigma and
resistance to MAT use. Challenges include lack of well-defined key components and limited
psychosocial services and care coordination/integration.

DISCUSSION

Author Manuscript

Addressing the current U.S. OUD disorder epidemic will require diverse approaches over
many years. Models of care that integrate MAT in primary care and other healthcare settings
have the potential to expand access to OUD treatment and decrease the personal and societal
impact of OUD. We identified 12 representative models of primary care-MAT integration
that may be considered for adaptation and expansion across diverse healthcare settings.
All models contained some degree of four key components: (1) pharmacological therapy; (2)
psychosocial services; (3) integration of care; and (4) education and outreach. Models varied
in relative emphasis of these components, though common themes included the importance
of a non-physician coordinator and use of tiered approaches. The ideal model of care for a
particular setting likely depends on local factors such as available expertise, the population
being served, proximity to an addiction center of excellence, reimbursement policies, and
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geography. Decisions about MAT models of care should therefore be individualized to
address the unique milieu of each implementation setting. It may be appropriate to combine
elements of different models of care (e.g., implement nurse care manager care coordination
within a Hub and Spoke model) or to link models of care (e.g., ED or inpatient based
screening and initiation of treatment linked with OBOT).

Author Manuscript

Most MAT models (10 of 12) provided sublingual buprenorphine/naltrexone
pharmacotherapy. Although implantable buprenorphine was approved by the Food and Drug
Administration in 2016, research on its use in primary care settings is lacking. Two
randomized trials demonstrate extended-release naltrexone efficacy for OUD in addiction
treatment settings (54, 55), but its effectiveness for OUD in primary care settings has not
been studied and use is limited. Expanding evidence-based, long-acting MAT options could
broaden patient choices, reduce risk of diversion, and decrease need for frequent follow-up
in appropriate patients.
As described in the full report (11), barriers to implementing MAT include lack of trained
primary care providers, reimbursement models that do not support care coordination and
psychosocial services, persistent stigma associated with MAT, and long travel times for
patients in rural areas. Current models of care utilize various strategies to address barriers,
such as integrating training and education, use of non-physicians, development of
reimbursement models to support MAT delivery, use of tele-education, tiered care models,
and engagement of stakeholders.

Author Manuscript

Our report has potential limitations. The specific models described are meant to provide a
representative taxonomy of ways to integrate MAT and primary care, rather than an
exhaustive list. No study has compared outcomes of different MAT models of care and some
models have not been reported in the published literature. Therefore, we supplemented
literature searches with Key Informant interviews and grey literature searches and utilized a
descriptive approach. Other challenges include overlapping characteristics of models of care,
variable levels of structure, and adaptation to specific settings.
Important areas of uncertainty, described in the full report (11), include optimal methods for
measuring quality of MAT care, assessment tools to better individualize care, optimal
psychosocial components of MAT, cost and cost effectiveness, methods for reducing
diversion, optimal methods for coordination and integration of care, and the effectiveness of
mid-level prescribing, newer MAT, and telehealth and telemedicine approaches. Research in
these areas would inform future efforts at dissemination and expansion of MAT in primary
care settings.
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In summary, existing MAT models of care can inform expanded implementation in primary
care settings. Decisions about adopting MAT models of care should consider the advantages
and disadvantages of each model, and should be individualized to address the unique milieu
of each implementation setting.
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Appendix A. Sample Questions for Key Informants
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Key Informant Perspective

Sample Questions

Researchers and Clinicians
(including Professional
Societies and Organizations)

Guiding Questions 1, 2, and 4 from full AHRQ report (11).
In addition:

Author Manuscript
Health Policy and
Implementation Arenas

1

What outcomes should be prioritized?

2

In your experience, what MAT models of care have been particularly
successful and why?

3

Are there models of care that are particularly suited (e.g., feasibility,
applicability) for rural or other underserved settings?

4

How would you categorize the components of MAT models of care?

5

What MAT models of care components are most critical for
effectiveness?

6

What are barriers to implementation of MAT in primary care settings?

7

What are specific barriers to implementation of community-based
psychosocial programs in MAT?

Author Manuscript

8

How could barriers to implementation be overcome?

9

Are you aware of new or innovative models of care that warrant
additional research?

10

What are key research needs to understand effectiveness and
implementation of MAT models of care?

11

What types of study designs would be useful for studying new or
innovative MAT models of care?

12

What is a meaningful length of followup?

13

Are there specific areas related to effectiveness or implementation of
MAT models of care that have been sufficiently studied to warrant a
systematic evidence review?

1

What outcomes of MAT are important from a health policy/payer
perspective?

2

What policies do payers put in place to influence use of MAT for
treatment of opioid use disorder?

3

How are decisions to cover or implement MAT made at a policy level
or at an institutional/clinical setting level?

4

What are some research questions about MAT that you would like
answered to inform policy and implementation decisions?

5

Are you considering new policies to improve the use of MAT,
particularly in primary care, including rural or other underserved
populations?

6

What are cost and/or economic efficiency considerations that impact
diffusion, decision-making, and/or conceptual thinking around MAT?
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Key Informant Perspective

Sample Questions

Patient Perspective

1

What values do patients place on various non-substance-use-related
outcomes and how do patients weigh trade-offs related to different
pharmacological and non-pharmacological approaches?

2

What factors or themes are most important to patients receiving MAT?

3

What components of MAT are important for patients to know, that they
may not be aware of?

4

What common experiences do patients in MAT programs describe?

5

Should the use of MAT programs be expanded; and if so, what settings
for patients are most amenable to the implementation of MAT?

6

What barriers do patients experience in obtaining MAT?

7

What suggestions do patients have for improving MAT models of care?

8

What are ethical, privacy, equity, or cost considerations that impact
patient’s use of MAT?

Author Manuscript

Abbreviation: MAT = medication-assisted treatment

Appendix B. Search Strategies
Database: Ovid MEDLINE

Author Manuscript
Author Manuscript

1.

exp Opiate Substitution Treatment

2.

exp Opioid-Related Disorders/dt, pc, px, rh, th

3.

methadone.mp. or exp Methadone

4.

buprenorphine.mp. or Buprenorphine

5.

naltrexone.mp. or Naltrexone

6.

suboxone.mp.

7.

3 or 4 or 5 or 6

8.

2 and 7

9.

(medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or
program*)).mp. [mp=title, abstract, original title, name of substance word,
subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier]

10.

((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2
(treatment* or therap* or regimen* or program* or interven*)).ti,ab.

11.

9 or 10

12.

2 and 11

13.

1 or 8 or 12

14.

limit 13 to english language

15.

exp Comprehensive Health Care/
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16.

exp Community Health Services/

17.

exp Outpatients/

18.

exp Ambulatory Care/

19.

exp Ambulatory Care Facilities/

20.

exp General Practice/

21.

general practitioners/or physicians, family/or physicians, primary care/

22.

exp Health Services Accessibility/

23.

15 or 16 or 17 or 18 or 19 or 20 or 21 or 22

24.

(((primary or ambulatory) adj3 care) or ((family or general) adj3 (medicine or
practice* or physician* or doctor* or practitioner* or provider*)) or outpatient*
or ((communit* or comprehensiv*) adj3 (health* or care))).mp.

25.

(rural* or underserv* or frontier* or (geograph* adj3 (isolat* or remot*))).mp.
[mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]

26.

24 or 25

27.

23 or 26

28.

14 and 27

29.

limit 28 to yr="2005 -Current"

30.

limit 28 to yr="1902 – 2004"

31.

limit 14 to systematic reviews

32.

limit 14 to (controlled clinical trial or guideline or randomized controlled trial)

33.

exp epidemiologic study/

34.

14 and 33

35.

Comparative Study/

36.

14 and 35

37.

exp "Outcome and Process Assessment (Health Care)"/

38.

14 and 37

39.

mo.fs.

40.

exp Death/

41.

exp Vital Statistics/

42.

39 or 40 or 41

43.

14 and 42
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44.

exp Evaluation Studies as Topic/

45.

14 and 44

46.

exp "costs and cost analysis"/

47.

14 and 46

48.

exp Sociological Factors/

49.

14 and 48

50.

exp quality of life/

51.

14 and 50

52.

exp health behavior/

53.

14 and 52

54.

exp attitude to health/

55.

14 and 54

56.

31 or 32 or 34 or 36 or 38 or 43 or 45 or 47 or 49 or 51 or 53 or 55

57.

28 or 56

Database: EBM Reviews – Cochrane Database of Systematic Reviews

Author Manuscript
Author Manuscript

1.

[exp Opiate Substitution Treatment/]

2.

[exp Opioid-Related Disorders/dt, pc, px, rh, th]

3.

methadone.mp. or exp Methadone/

4.

buprenorphine.mp. or Buprenorphine/

5.

naltrexone.mp. or Naltrexone/

6.

suboxone.mp.

7.

3 or 4 or 5 or 6

8.

2 and 7

9.

(medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or
program*)).mp.

10.

((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2
(treatment* or therap* or regimen* or program* or interven*)).ti,ab.

11.

9 or 10

12.

1 or 8 or 11

Database: EBM Reviews – Cochrane Central Register of Controlled Trials
1.

exp Opiate Substitution Treatment/
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2.

exp Opioid-Related Disorders/dt, pc, px, rh, th

3.

methadone.mp. or exp Methadone/

4.

buprenorphine.mp. or Buprenorphine/

5.

naltrexone.mp. or Naltrexone/

6.

suboxone.mp.

7.

3 or 4 or 5 or 6

8.

2 and 7

9.

(medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or
program*)).mp.

10.

((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2
(treatment* or therap* or regimen* or program* or interven*)).ti,ab.

11.

9 or 10

12.

1 or 8 or 11

Database: PsycINFO

Author Manuscript
Author Manuscript

1.

exp opiates/

2.

exp drug rehabilitation/

3.

exp drug dependency/

4.

2 or 3

5.

exp drug therapy/

6.

exp methadone maintenance/

7.

methadone.mp. or exp Methadone/

8.

buprenorphine.mp. or Buprenorphine/

9.

naltrexone.mp. or Naltrexone/

10.

suboxone.mp.

11.

5 or 6 or 7 or 8 or 9 or 10

12.

1 and 4 and 11

13.

(medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or
program*)).mp.

14.

((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2
(treatment* or therap* or regimen* or program* or interven*)).ti,ab.

15.

13 or 14

16.

1 and 4 and 15
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17.

12 or 16

18.

limit 17 to english language

19.

exp Primary Health Care/

20.

exp community services/

21.

exp Outpatients/

22.

exp outpatient treatment/

23.

exp Maintenance Therapy/

24.

exp Ambulatory Care/

25.

exp Ambulatory Care Facilities/

26.

exp General Practitioners/

27.

exp Family Medicine/

28.

exp Family Physicians/

29.

exp Treatment Barriers/

30.

exp health disparities/

31.

exp health care utilization/

32.

19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31

33.

(((primary or ambulatory) adj3 care) or ((family or general) adj3 (medicine or
practice* or physician* or doctor* or practitioner* or provider*)) or outpatient*
or ((communit* or comprehensiv*) adj3 (health* or care))).mp.

34.

(rural* or underserv* or frontier* or (geograph* adj3 (isolat* or remot*))).mp.

35.

33 or 34

36.

32 or 35

37.

18 and 36

38.

limit 18 to systematic reviews

39.

exp treatment outcomes/or exp treatment effectiveness evaluation/

40.

18 and 39

41.

exp "Death and Dying"/

42.

exp mortality rate/

43.

41 or 42

44.

18 and 43

45.

exp "costs and cost analysis"/

46.

18 and 45
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47.

exp Sociocultural Factors/

48.

exp socioeconomic status/

49.

47 or 48

50.

18 and 49

51.

exp quality of life/

52.

18 and 51

53.

exp health behavior/

54.

18 and 53

55.

exp attitudes/

56.

18 and 55

57.

38 or 40 or 44 or 46 or 50 or 52 or 54 or 56

58.

37 or 57

CINAHL
S1 (MH "Substance Use Disorders+")
S2 (MH "Narcotics+")
S3 S1 AND S2
S4 "methadone"

Author Manuscript

S5 "buprenorphine"
S6 "naltrexone"
S7 suboxone
S8 S4 OR S5 OR S6 OR S7
S9 S1 AND S8
S10 (medicat* n3 assist* n3 (treat* or therap* or regimen* or interven* or
program*))
S11 ((opiate* or opioid* or narcotic*) n2 (substitut* or replac* or maint*) n2
(treatment* or therap* or regimen* or program* or interven*))

Author Manuscript

S12 S10 OR S11
S13 S1 AND S12
S14 S3 OR S9 OR S13
S15 S3 OR S9 OR S13
S16 (MH "Primary Health Care")
S17 (MH "Community Health Services+")
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S18 (MH "Outpatients") OR (MH "Outpatient Service") OR (MH "Ambulatory Care
Facilities+")
S19 (MH "Family Practice")
S20 (MH "Physicians, Family")
S21 (MH "Health Services Accessibility+")
S22 S16 OR S17 OR S18 OR S19 OR S20 OR S21
S23 (((primary or ambulatory) n3 care) or ((family or general) n3 (medicine or
practice* or physician* or doctor* or practitioner* or provider*)) or outpatient* or
((communit* or comprehensiv*) n3 (health* or care)))
S24 (rural* or underserv* or frontier* or (geograph* n3 (isolat* or remot*)))

Author Manuscript

S25 S23 OR S24
S26 S22 OR S25
S27 S15 AND S26
S28 (MH "Systematic Review")
S29 (MH "Meta Analysis")
S30 (MH "Practice Guidelines") OR (MH "Guideline Adherence")
S31 (MH "Randomized Controlled Trials")
S32 (MH "Epidemiological Research+")

Author Manuscript

S33 (MH "Prospective Studies+")
S34 S28 OR S29 OR S30 OR S31 OR S32 OR S33
S35 S15 AND S34
S36 (MH "Outcomes (Health Care)+")
S37 (MH "Vital Statistics+")
S38 (MH "Evaluation Research+")
S39 (MH "Costs and Cost Analysis+")
S40 (MH "Socioeconomic Factors+")
S41 (MH "Cultural Values")

Author Manuscript

S42 (MH "Quality of Life+")
S43 (MH "Quality-Adjusted Life Years")
S44 (MH "Health Behavior+")
S45 (MH "Attitude+")
S46 S36 OR S37 OR S38 OR S42 OR S43
S47 S15 AND S46
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S48 S15 AND S46

Author Manuscript

S49 S15 AND S34
S50 s48 NOT s49

SocINDEX
S1 (MH "Substance Use Disorders+")
S2 (MH "Narcotics+")
S3 S1 AND S2
S4 "methadone"
S5 "buprenorphine"

Author Manuscript

S6 "naltrexone"
S7 suboxone
S8 S4 OR S5 OR S6 OR S7
S9 S1 AND S8
S10 (medicat* n3 assist* n3 (treat* or therap* or regimen* or interven* or
program*))
S11 ((opiate* or opioid* or narcotic*) n2 (substitut* or replac* or
maint*) n2 (treatment* or therap* or regimen* or program* or interven*))

Author Manuscript

S12 S10 OR S11
S13 S9 OR S12
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Table 1

Author Manuscript

Key Informants (n=11)
Stakeholder

Representative

Clinicians with experience treating OUD in primary care
(n=5)

Policy Experts in OUD treatment implementation (n=4)

•

Internal medicine/addictionologist

•

Family medicine/addictionologist

•

Addiction psychiatrist

•

Psychologist

•

Registered nurse

•

Health Resources and Services Administration HIV/AIDS Bureau

Author Manuscript

•

Substance Abuse and Mental Health Services Administration

•

National Institute on Drug Abuse

•

National Association of State Alcohol and Drug Abuse Directors

Professional Societies (n=1)

•

American Association of Opioid Treatment Providers

Patient Perspective (n=1)

•

Patient in recovery who also directs an opioid treatment program

Author Manuscript
Author Manuscript
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Table 2

Author Manuscript

Sources for MAT models of care
Model

Published Literature

Grey Literature

Practice-Based Models

Author Manuscript

1) Office-based
Opioid
Treatment
(OBOT)

Fiellin, 2002 (16)*
Fiellin, 2006 (15)*
Fiellin, 2008 (14)

–

2)
BuprenorphineHIV
Evaluation and
Support
(BHIVES)
Collaborative
Model

Altice, 2011 (17)
Chaudhry, 2011 (56)
Cheever, 2011 (57)
Egan, 2011 (58)
Fiellin, 2011 (18)
Finkelstein, 2011 (59)
Friedland, 2011 (60)
Korthuis, 2011 (19)
Korthuis, 2011 (20)
Lucas, 2010 (21)*
Lum, 2011 (61)
Schackman, 2011 (62)
Sullivan, 2006 (23)*
Sullivan, 2011 (63)
Vergara-Rodriguez,
2011 (64)
Weiss, 2011 (25)
Weiss, 2011 (26)

https://www.careacttarget.org/library/beehive-buprenorphine-program-tools (24)
http://www.slideshare.net/SarahCookRaymond/buprenorphine-therapy-in-the-hiv-pruma (22)

3) One Stop
Shop Model

–

http://www.lifespringhealthsystems.org/about-us/locations/ (33)

4) Integrated
Prenatal Care
and MAT
(Expert
suggestion)

–

–

System-Based Models

Author Manuscript
Author Manuscript

5) Hub and
Spoke Model
(Vermont)

–

https://www.pcpcc.org/initiative/vermont-hub-and-spokes-health-homes (39) http://www.healthvermont.gov/adap/documents/HUB
http://www.leg.state.vt.us/reports/2014ExternalReports/299315.pdf (38)
http://www.achp.org/wp-content/uploads/Vermont-Health-Homes-for-Opiate-Addiction-September-2013.pdf (41)

6) Medicaid
Home Model
For Those With
Opioid Use
Disorder

–

https://www.medicaid.gov/Federal-Policy-Guidance/Downloads/CIB-07-11-2014.pdf (36)
https://www.medicaid.gov/state-resource-center/medicaid-state-technical-assistance/health-homes-technical-assistance/downloads/

7) Project
Extension for
Community
Healthcare
Outcomes
(ECHO) (New
Mexico)

Komaromy, 2016 (42)

http://echo.unm.edu/wp-content/uploads/2014/10/Opioid-Abuse-and-Addiction-Management-Protocol.pdf (43)
http://www.aafp.org/news/chapter-of-the-month/20140930nmafp-chapspot.html (44)

8)
Collaborative
Opioid
Prescribing
(Co-OP) Model
(Maryland)

Stoller, 2015 (46)

http://www.atforum.com/pdf/CoOPtalkforONDCP_SAMHSAAug2015Stoller.pdf (45)

9)
Massachusetts
Nurse Case
Manager
Model

Alford, 2007 (65)
Alford, 2011 (47)
LaBelle, 2016 (48)

http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/get-help-types-of-treatment.html (66)

10) Emergency
Department

D’Onofrio, 2015 (49)*

–
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Author Manuscript

Published Literature

Grey Literature

11) Inpatient
Initiation of
MAT

Liebschutz, 2014 (50)*

–

12) Southern
Oregon Model

–

http://www.oregonpainguidance.org/ (67)

(ED) Initiation
of OBOT

Abbreviation: MAT = medication-assisted treatment.

*

Randomized controlled trial evaluating the model of care

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript

Author Manuscript

Author Manuscript

Summary

Glue person
(typically nurse)
with expertise in
buprenorphine
working in
collaboration
with primary
care clinician

Chronic care
model for
providing
buprenorphine/
naloxone in
HIV primary
care clinic
setting

Integrated
model based in
mental health
clinic to provide
“one-stop”
shopping
including
management of
HIV/HCV
infection and
plans for MAT
in progress

1) Office-based
Opioid
Treatment
(OBOT)

2)
BuprenorphineHIV Evaluation
and Support
(BHIVES)
Collaborative
Model

3) One Stop
Shop Model

Practice-Based Models

Model

Ann Intern Med. Author manuscript; available in PMC 2017 August 21.
Primarily naltrexone

Buprenorphine/naloxone

Primarily buprenorphine/naloxone

Pharmacological Component

Education to increase number of
waivered physicians

Patient and provider educational
material available online

Not a major component

Education/Outreach Component

Treatment for
OUD, mental
health, and
primary care
(including
HIV/HCV care)
provided in same
setting. Peer
navigators and
social workers
provide
coordination with

Treatment for
OUD and primary
care, including
HIV care
integrated in same
setting. Clinical
coordinator “glue
person”
coordinates care;
works in
conjunction with
primary care
provider.
Provision of HIV
care may be by the
primary care
provider or
another provider
working with the
primary care
provider

Glue person
(typically nurse)
instrumental for
coordinating and
integrating care,
including primary
care and mental
health

Coordination/
Integration of
Care Component

Overview of MAT models of care for OUD in primary care (including rural or other underserved settings)

Centered in mental health
clinic that provides
comprehensive
psychological services;
psychiatrist once a week

On-site psychological
services variable, including
individual and group
counseling

Physician counseling
monthly; some
psychological services
provided on-site by glue
person or other staff. Other
psychosocial services vary,
including integrated CBT,
Motivational Enhancement
Therapy; some
psychosocial services
offsite

Psychosocial Component

Syringe exchange and
other services also
available

Coordination with
OTP for patients
switching to or from
methadone

Other Component(s)

Author Manuscript

Table 3
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Centralized
intake and
initial
management
(buprenorphine
induction) at
“hub” and then
patients
connected to
“spokes” in
community for
ongoing
management

A flexible
model that
provides MAT
in combination
with behavioral
health therapies
and integrated
with primary
care.

Model of care
for linking
primary care
clinics in rural
areas with a
university health
system,
emphasizing

5) Hub and
Spoke Model
(Vermont)

6) Medicaid
Home Model
For Those With
Opioid Use
Disorder

7) Project
Extension for
Community
Healthcare
Outcomes
(ECHO) (New
Mexico)

System-Based Models

Model
providing
prenatal care to
pregnant women
who are treated
with
buprenorphine

Author Manuscript

4) Integrated
Prenatal Care
and MAT

Author Manuscript
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Primarily buprenorphine/naloxone

Primarily buprenorphine/naloxone

Primarily buprenorphine/naloxone

Buprenorphine

Pharmacological Component

Mentored buprenorphine
prescribing for providers, including
Internet-based, audiovisual
network for provider education.
Free buprenorphine training
provided several times a year.
ECHO staff provide patient

Provider and community education
emphasized to increase uptake and
decrease stigma

Outreach to prescribers in the
community to increase number of
buprenorphine-waivered
physicians.

Not a major component

Education/Outreach Component

NP/PA performs
initial evaluation
and screening
educate patient
and refer to
collaborating
physician for
treatment. NP/PA

Required
component, but
mechanism of
coordination
varies

Coordination/
integration
between hub and
spoke as well as
within each
primary care site
“spoke.”
Registered nurse
clinician case
manager, and/or
care connector
(peer, behavioral
health specialist)
for coordination/
integration of care
at spokes.

Primary care
clinic provides
MAT, as well as
prenatal and postpartum care; care
continued in
office-based
setting for 1 year
after birth. In
some programs
women can work
with doulas

primary care
providers

Coordination/
Integration of
Care Component

Author Manuscript

Summary

Counseling and behavioral
therapies offered from all
ECHO team members
including CHWs, although
CHWs and NPs provide
education/support,
psychosocial support
including 12 step

Six core psychosocial
services are required:
comprehensive care
management, care
coordination, health
promotion, comprehensive
transitional care/follow-up,
individual and family
support and referral to
community and social
support services.

Embedded in spoke sites,
including social workers,
counseling, and
community health teams.

Services provided on-site
or via partnering OTP

Psychosocial Component

Refer any patients
with high or moderate
risk scores for opioid
use to NP for further
assessment and/or
referral to OTP

Some telehealth
services offered

Hubs provides
consultative services
and available to
manage clinically
complex patients,
support tapering off
MAT, or prescribe
methadone, if needed

Other Component(s)

Author Manuscript

Model
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Author Manuscript

Links opioid
treatment
programs with
office-based
buprenorphine
providers; initial
intake,
induction, and
stabilization
performed at
OTP then
shifted to
primary care
clinic

A primary-care
based model
that teams nurse
care managers
with primary
care physicians;
nurse care
managers
generally
perform initial
screening,
intake,
education,
observed/
supports
induction,
followup,
maintenance,
stabilization,
and medical
management
with the
physician and
team.

8) Collaborative
Opioid
Prescribing
(Co-OP) Model
(Maryland)

9)
Massachusetts
Nurse Case
Manager Model

nurse
practitioner or
physician
assistant
screening and
MAT (physician
prescribing)
combined with
counseling and
behavioral
therapies.

Author Manuscript
Primarily buprenorphine/naloxone, with
integration of extended-release naltrexone
in last two years

Buprenorphine/naloxone

Pharmacological Component

A training program exists to get
more physicians, especially
residents, and also faculty on
board. Department of Public Health
trains staff on best practices. Nurse
care managers receive 8 hours of
training in MAT, shadowing in
model MAT site, site visits, email
and phone support, case review,
quarterly trainings, and addiction
list server.

Outreach performed by counselors
to community physicians

education one-to-one or in group
setting.

Education/Outreach Component

Nurse care
managers (RN or
FNP) manage 100
to 125 patients
alongside primary
care clinicians,
with assistance
from a medical
assistant.
Alternatively, care
partners (usually
Master’s level
individuals) who
assist the primary
care staff with
screening, brief
intervention, and
referral to
treatment.

Initial assessment,
psychosocial
treatment, and
expert
consultation
initiated in drug
treatment program
and patients
transitioned to
primary care in
federally qualified
health center
following
stabilization

performs
monitoring
treatment and
followup
appointments
including labs,
urine testing,
monitoring,
patient education
and support and
other coordination
(e.g., vaccinations)

Coordination/
Integration of
Care Component

Author Manuscript

Summary

Psychological services are
integrated on-site or nearby

Provided concurrently via
OTP, including ongoing
counseling and monitoring

programs, crisis
counseling, referrals, and
relapse-prevention plans.

Psychosocial Component

Patients who require
higher level of care
can be expedited into
an OTP, assistance
with transfers of care,
day support programs

In Baltimore, supports
to facilitate access to
health coverage
through Medicaid and
to coordinate care
through HealthCare
Access Maryland

Other Component(s)

Author Manuscript

Model
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Model involving
identification of
OUD in the
hospital and
connecting
patients to
office-based
MAT and
primary care

A local and
informal model
for delivery of
MAT in a rural
primary care
network

11) Inpatient
Initiation of
MAT

12) Southern
Oregon Model

Almost exclusively buprenorphine/naloxone

Buprenorphine/naloxone, naltrexone

Buprenorphine/naloxone

A group of local stakeholders from
many perspectives who prescribe
opioids (Oregon Pain Guidance)
meets regularly to develop
guidance and provide education.

Not a major component

Not a major component

Education/Outreach Component

Relatively limited
support for
coordination/
integration of care

MAT started by
multidisciplinary
addiction consult
service during
medical
hospitalization and
connected with
primary care.
Treatment
continued in
primary care;
some programs
have
buprenorphine
“bridge” clinic
prior to transition
to primary care.

OUD identified in
ED and patients
started on
buprenorphine and
connected to
ongoing OBOT
provided by
physicians and
nurses for 10
weeks, then
transferred to
office-based
ongoing
maintenance
treatment or
detoxification.

Coordination/
Integration of
Care Component

On-site licensed clinical
social worker with
experience in treating
patients for pain and
addiction, not necessarily
in MAT.

Provided at primary care
site

“Medical management”
counseling visits with
physician and nurse

Psychosocial Component

Access to OTPs for
complex patients not
formally integrated.

Other Component(s)

Abbreviations: CBT = cognitive behavioral therapy; CHW = community health worker; DPH = Department of Public Health; ED = emergency department; FNP = family nurse practitioner; HCV =
hepatitis C virus; MAT = medication-assisted treatment; NP = nurse practitioner; OTP = opioid treatment program; OUD = opioid use disorder; PA = physician assistant; RN=registered nurse.

Model involving
ED
identification of
OUD;
buprenorphine/
naloxone
induction
initiated in ED;
coordination
with OBOT,
nurse with
expertise in
buprenorphine
working in
collaboration
with primary
care clinician

Author Manuscript

10) Emergency
Department
(ED) Initiation
of OBOT

Author Manuscript
Pharmacological Component

Author Manuscript

Summary

Author Manuscript

Model
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